Navigating Risks and Rewards- Immunotherapies in Myeloma Care | Adam Cohen, MD

Navigating Risks and Rewards- Immunotherapies in Myeloma Care | Adam Cohen, MD
Myeloma Philadelphia HealthTree Round Table - Audience Q&A with Faculty
More Options, More Hope: The New Reality for Newly Diagnosed Myeloma | Gurbakhash Kaur, MD #myeloma
The Expansion of Bispecifics in Myeloma -What’s Next? Alfred Garfall, MD
Innovations in Myeloma Therapies: Promise of ADCs, CELMoDs, BCL2 Inhibitors, & SINEs | Dan Vogl, MD
Multiple Myeloma Q & A with Dr. Patel for the Relapsed/Refractory Population | Krina Patel, MD
Expanding Myeloma Treatments: Power of Bispecific & Trispecific Antibodies| Dr. Aravind Ramakrishnan
Personalizing Treatment from Diagnosis- Charting Your Myeloma Journey | William Matsui, MD
What is plasma cell percentage? Why is it useful to have this information?